AbCellera is an antibody discovery and development company that develops antibody therapeutics to improve patient outcomes.
AbCellera has raised $515.8M in total funding. The most recent round was Grant. The last funding was announced in May 2023.
AbCellera's investors include Founders Fund, Eli Lilly, Bill & Melinda Gates Foundation, DCVC Bio, Government of Canada.
AbCellera is headquartered in Vancouver, Canada.
AbCellera is an antibody discovery and development company that develops antibody therapeutics to improve patient outcomes.
AbCellera is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AbCellera — Funding & Investors." VCBacked, May 24, 2023, https://www.vcbacked.co/company/abcellera. Accessed November 13, 2026.
VCBacked. (2023). AbCellera — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/abcellera
{{cite web |title=AbCellera — Funding & Investors |url=https://www.vcbacked.co/company/abcellera |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at AbCellera? Request a listing update